Next Article in Journal
Potential of DPD ((S)-4,5-dihydroxy-2,3-pentanedione) Analogs in Microparticulate Formulation as Vaccine Adjuvants
Next Article in Special Issue
New Approaches to Overcoming Antimicrobial Resistance in Endophthalmitis
Previous Article in Journal
Impact of a Moderate CYP3A4 Inducer (Bosentan) on Lurbinectedin Pharmacokinetics and Safety in Patients with Advanced Solid Tumors: An Open-Label, Two-Way, Crossover, Phase Ib Drug–Drug Interaction Study
 
 
Article

Article Versions Notes

Pharmaceuticals 2024, 17(2), 183; https://doi.org/10.3390/ph17020183
Action Date Notes Link
article xml file uploaded 30 January 2024 15:04 CET Original file -
article xml uploaded. 30 January 2024 15:04 CET Update https://www.mdpi.com/1424-8247/17/2/183/xml
article pdf uploaded. 30 January 2024 15:04 CET Version of Record https://www.mdpi.com/1424-8247/17/2/183/pdf
article html file updated 30 January 2024 15:05 CET Original file https://www.mdpi.com/1424-8247/17/2/183/html
Back to TopTop